Clinical trials: TAS 102
Colonrectal Cancer (CRC)
Nelmastobart in Combination With Tas-102 and Bevacizumab in Recurrent/Metastatic Colorectal Cancer
Nelmastobart（hSTC810） is a novel humanized monoclonal antibody that fuses on IgG4 and targets a novel immune checkpoint protein, BTN1A1+.This is an phase Ib bridging trial conducted in China to assess the safety, tolerability…
- Trial name
- NCT07656038
- Testing
- Nelmastobart in combination with TAS-102 and Bevacizumab
- Volunteers
- 45 people
- Sponsor
- STCube, Inc.
Colorectal Cancer (CRC)
Efficacy and Safety of Trifluridine/Tipiracil (TAS-102) Combined With Bevacizumab and Serplulimab in Patients With Metastatic Colorectal Cancer Undergoing Cytoreductive Surgery: A Single-Arm, Single-Center Clinical Study
Colorectal cancer (CRC) is one of the most common malignant tumors. With the rapid development of China's economy, people's living standards have been significantly improved, and lifestyles and dietary structures have changed.
- Trial name
- NCT06882915
- Testing
- Trifluridine/tipiracil (TAS-102) combined with bevacizumab and ptemizumab
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Neuroendocrine Tumors, Neoplasms
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
The goal of this study is to establish maximum tolerated doses/recommended phase 2 dose (RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to evaluate the safety profile of this drug…
- Conditions
- Neuroendocrine Tumors, Neoplasms, Cancer, Tumors
- Trial name
- NCT02943733
- Testing
- TAS-102, Temozolomide, Filgrastim
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Wisconsin, Madison
Colorectal Neoplasms
SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer
This phase II trial studies how well stereotactic body radiotherapy (SBRT) followed by a combination of an immune checkpoint inhibitor (sintilimab), bevacizumab, and trifluridine/tipiracil (TAS-102) works as third-line treatment…
- Trial name
- BEST (NCT07535632)
- Testing
- SBRT, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Shanghai Zhongshan Hospital
High-grade Extra Pulmonary Neuroendocrine Cancer
TAS-102 in Extrapulmonary Neuroendocrine Carcinoma
The purpose of this study is to test the safety and efficacy of drug, TAS-102 (trifluridine/tipiracil), in patients with extrapulmonary (outside the lung) high-grade neuroendocrine cancer.
- Trial name
- TAS-102 NEC (NCT04042714)
- Testing
- All patients- TAS-102
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Baylor Research Institute
Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of trametinib and trifluridine and tipiracil hydrochloride in treating patients with colon or rectal cancer that has spread to other places in the body…
- Conditions
- Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma, RAS Family Gene Mutation
- Trial name
- NCT03317119
- Testing
- Laboratory Biomarker Analysis, Trametinib, Trifluridine and Tipiracil Hydrochloride
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- City of Hope Medical Center
Pancreas Cancer
TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
This is a prospective phase II, single arm clinical trial conducted in Queen Mary Hospital (Hong Kong) assessing the efficacy and safety of TAS-102 in advanced or metastatic pancreatic cancer patients.
- Trial name
- NCT04923529
- Testing
- TAS 102
- Where
- Hong Kong
- Volunteers
- 28 people
- Sponsor
- The University of Hong Kong
Metastatic Colorectal Cancer
LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy
Prospective cohort of patients treated with trifluridine/tipiracil, maximal sample size 250 patients. It is expected, that 89 patients will experience a grade 3-4 neutropenia and will be included in the phase II.
- Trial name
- LONGBOARD (NCT04166604)
- Testing
- Trifluridine/Tipiracil
- Where
- 22 sites in France
- Volunteers
- 176 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Advanced or Metastatic Solid Tumors
A Phase I Study of TAS-102 in Solid Tumors
The primary objective of this study is to evaluate the pharmacokinetics of TAS-102 after single and multiple dose in Chinese patients with solid tumor.
- Trial name
- NCT02261532
- Testing
- TAS-102
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma
A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
This phase Ib trial studies the safety and side effects of a vaccine (PolyPEPI1018 vaccine) in combination with TAS-102 in treating patients with colorectal that has spread to other parts of the body (metastatic).
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Microsatellite Stable Colon Carcinoma
- Trial name
- NCT05130060
- Testing
- Colorectal Cancer Peptide Vaccine PolyPEPI1018, Trifluridine and Tipiracil Hydrochloride
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Refractory Metastatic Colorectal Cancer
Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer
Combined chemotherapy and radiofrequency electromagnetic field treatment for patients with liver dominant refractory metastatic colorectal cancer
- Trial name
- Live-RF (NCT05991102)
- Testing
- Radiofrequency electromagnetic field treatment
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Charite University, Berlin, Germany
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of hepatic impairment.
- Trial name
- NCT02301104
- Testing
- TAS-102
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Taiho Oncology, Inc.
Immunotherapy, Colorectal Cancer
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
To evaluate the clinical efficacy and safety of TAS-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.
- Trial name
- NCT05314101
- Testing
- Tislelizumab, bevacizumab, TAS-102
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Cancer Hospital
TAS 102, Regorafenib
TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
This is a single-arm, multicentre real-world observational study of TAS-102 in combination with regorafenib or fruquintinib for third-line and above advanced colorectal cancer.
- Conditions
- TAS 102, Regorafenib, Fruquintinib, Gastrointestinal Tumours
- Trial name
- NCT05993702
- Testing
- regorafenib, fruquintinib
- Volunteers
- 45 people
- Sponsor
- China Medical University, China
Metastatic Colorectal Cancer (mCRC)
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen
This is an open label, randomized, two arm, multi-center study to explore the effect of leronlimab on the overall response rate/ overall survival and safety and tolerability when used in combination with trifluridine and…
- Trial name
- CLOVER (NCT06699836)
- Testing
- 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 66 people
- Sponsor
- CytoDyn, Inc.
Colorectal Neoplasms
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite…
- Trial name
- RELATIVITY-123 (NCT05328908)
- Testing
- Nivolumab-relatlimab FDC, Regorafenib, TAS-102
- Where
- 139 sites in United States, Argentina and 20 more
- Volunteers
- 769 people
- Sponsor
- Bristol-Myers Squibb
EFS, pCR Rate
Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer
5-Fluorouracil (5-FU) based chemoradiotherapy is regarded a standard perioperative treatment in locally advanced rectal cancer, but the effective rate still low.
- Trial name
- NCT07090031
- Testing
- TAS-102 in combination with oxaliplatin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Qingdao Central Hospital
Rectal Cancer
SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer
TASOX can be safely and efficaciously delivered after short course radiation, resulting in significant pathologic downstaging, allowing for an R0 pelvic resection, and providing local control in appropriately selected stage…
- Trial name
- SHORT (NCT04417699)
- Testing
- TAS 102, Oxaliplatin
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Providence Health & Services
Gastric Cancer
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib combined with TAS102 for second-line treatment of advanced gastric cancer.
- Trial name
- NCT06102785
- Testing
- Fruquintinib, TAS102
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Squamous Cell Lung Carcinoma
TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)
This is a non-randomized, open label, sequentially enrolling phase II study with a Simon two-step enrollment design to evaluate the activity of TAS-102 in previously treated unresectable or metastatic squamous non-small cell…
- Trial name
- NCT02920476
- Testing
- TAS-102
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Florida